As we know, a substance is called a drug when it has scientifically proven and well documented efficacy and safety profile to reduce both mortality and morbidity of patients. Any fraud or negligence in the drug quality standards, for whatever may be the reasons or wherever these take place, is a fraud on patients and should warrant zero tolerance.
A perception survey on drug quality:
According to a poll released in 2010 by the ‘Pew Charitable Trusts’s Prescription Project’ of the United States:
- More than three out of four voters are confident that prescription drugs made in the USA are free from contamination
- While less than one in 10 feel confident about medications made in India or China.
- 54 percent of Americans distrusted Indian drugs and 70 percent distrusted Chinese drugs.
- “When you buy a shirt, it will say right on the label where it was made, but when you get a pharmaceutical, you don’t know.”
Despite all these, the survey points out that in 2007, 68 percent of the ingredients of all drugs sold worldwide came from India or China, as compared to 49 percent in 2004.
Experts comment that USFDA does not have either people or resources required to monitor manufacturing in the geographically widespread locations, as these are today.
Recent spate of charges against Indian pharmaceutical companies – a vindication?
Recent spate of charges against some top ranked Indian companies, will further dent the image of India not just in the United States or Europe, but also as a pharmacy of high quality yet low cost generic drugs for the developing countries of the world.
In May 2013, well known India-based pharma major Ranbaxy reported to have pleaded guilty to criminal charges of manufacturing and distributing some adulterated medicines, produced at its Paonta Sahib and Dewas, facilities and agreed to US$ 500-millon settlement. Can this be considered as a vindication of the above perception on the quality of ‘made in India’ drugs?
The view of WHO:
Interestingly the World Health Organisation (WHO) even after the above USFDA indictment has commented that at present it has no evidence that Ranbaxy manufactured medicines that are currently prequalified by WHO are of unacceptable quality.
Indian drug regulator initiates action:
It is good to know that the Drugs Controller General of India (DCGI) and the Ministry of Health will reportedly decide the way forward in this matter on completion of a fact-finding study initiated by the Central Drugs Standards Control Organization (CDSCO) on the subject.
Other incidents in India:
Following are examples of other reported serious regulatory violations involving the domestic pharmaceutical companies:
|
No. |
Year |
Company |
Issue |
Status |
| 2009 | Lupin | USFDA warning for Mandideep plant | Resolved in 2010 | |
| 2010 | Claris Life Sciences | USFDA ban products for manufacturing norms violations | Ban revoked in 2012 | |
| 2011 | Zydus Cadila | USFDA warns Co. over Moraiya, Gujarat Facility | Ban revoked in 2012 | |
| 2011 | Dr Reddy’s | USFDA bans sale of drugs from Mexico facility | Ban revoked in 2012 | |
| 2013 | Jubilant Life Sciences | Gets USFDA warning for Canada facility | Company taking corrective steps | |
| 2013 | Wockhardt | Banned from exporting products from its Aurangabad factory to the US due to quality concerns | In discussion |
Source: The Economic Times (May 22, 2013), Financial Express (May 25, 2013)
Though some other countries also have faced bans from exporting products, it cannot be taken, I reckon, as any consolation by anyone.
A Mumbai Hospital demonstrated the mood of zero tolerance:
The above expression of good intent should not just remain as a ‘lip service’. Indian drug regulator is expected to take a leaf out of all these allegations and initiate appropriate audit as required. Otherwise, exhibiting zero tolerance, like Jaslok Hospital of Mumbai, many other institutions will ask their doctors not to prescribe products of these companies to protect patients’ interest. More hospitals reportedly are mulling similar action against Ranbaxy.
IMA expresses apprehension:
Even ‘The Indian Medical Association (IMA)’ has reportedly asked the DCGI to investigate quality of medicines manufactured by Ranbaxy.
It happens in the ‘heartland’ too just as in the ‘hinterland’:
Contrary to the above poll released in 2010 by the ‘Pew Charitable Trusts’s Prescription Project’, pointing accusing fingers, in this respect, exclusively to India and China, may not be just fair. Incidents of such regulatory violations are not just restricted to Indian pharmaceutical companies either. Unfortunately, these happen with the global majors too.
None of these should be condoned in any way by anyone and attract as much global publicity, public wrath and zero tolerance, as all these would possibly deserve.
Following are some examples:
|
No |
Company |
Issues with USFDA |
Consent decree signed (year) |
Issue status |
Penalty amount |
| Schering-Plough | GMP violations affecting four manufacturing sites and 125 products |
Yes (2002) |
Closed (2007) |
$500 Mn. | |
| GlaxoSmithKline | Manufacturing deficiencies found at Puerto Rico facility |
Yes (2005) |
Pending |
$650 Mn. Bond | |
| Wyeth | GMP violations at plant in Pennsylvania and New York which were producing FluShield |
Yes (2000) |
Pending |
$297 Mn. Plus 18.5% of sales of FluShield | |
| Abbott Labs | Non-conformance with quality system regulations for in vitro diagnostic products at an Illinois facility |
Yes (1999) |
Pending |
$212 Mn. | |
| Boehringer Ingelheim | To bring its Ohio facility into compliance with regulatory requirements |
Yes (2013) |
Pending |
Not specified |
Source: Financial Express (May 25, 2013)
Further, in December 1998 the US FDA reportedly had stopped shipments of Abbott Laboratories’ clot-busting drug Abbokinase till the company had resolved undisclosed manufacturing problems at its plant. Abbott subsequently resolved this to the satisfaction of the drug regulator.
Even end May 2011, the USFDA reportedly raised concerns about contamination of drugs of the American pharmaceutical major – Hospira, at its Indian manufacturing facility.This issue was highlighted as the latest in a string of manufacturing and quality problems dogging the company since 2010.
American lawmakers demand thorough review of USFDA oversight procedures:
Pressure has reportedly started mounting in the United States for a thorough review into the effectiveness of oversight procedures for all bulk drugs and formulations manufactured in foreign facilities.
Simultaneously, there is also a specific demand for an in-depth review of all actions of the US regulator for so many years, which allowed Ranbaxy’s ‘massive fraud to remain unchecked’.
Beyond regulatory oversight, need robust internal system driven model as a fire-wall:
To address such issues only drug regulators interventions may not be just enough, maintaining total integrity of ‘Supply Chain’ of an organization proactively in a well structured, fool-proof and a system-driven way, will continue to play the most critical role. This will help creating ‘fire-wall’, which will be difficult to breach.
The scope of Supply Chain:
The scope of ‘Supply Chain’, which is comprised of the entire network of entities from vendors who supply raw and packaging materials, manufacturers who convert these materials into medicines, together with warehouses, distributors, retailers and healthcare centers who will reach these medicines ultimately to patients exactly the way these will deserve.
Thus, just not in the manufacturing process, any breach of security at any place of the supply chain can cause serious problems to patients.
Accordingly, pharmaceutical companies need to adequately invest along with appropriate staff training programs to ensure that the Supply Chain Integrity is maintained, always.
Supply Chain Security (SCS) is critical:
SCS, therefore, deserves to be of prime importance for the pharmaceutical companies across the globe. Recent high profile SCS related cases, as mentioned above, have exposed the vulnerability in addressing this global menace effectively.
All pharmaceutical players should realize that not just ‘show-off’, an effective integrated approach is of paramount importance to eliminate this crime syndicate, which is taking lives of millions of patients the world over.
Mixing-up counterfeit drugs with this menace may not be prudent:
Shouting for counterfeit drugs involving mainly intellectual property related issues, may be important, but will in no way help resolving self-created menaces arising out of breach of supply chain integrity endangering million of lives, in another way.
Though an expensive process, can’t be compromised:
It is worth repeating, securing pharmaceutical supply chain on a continuous basis is of critical importance for all the pharmaceutical players across the globe. However, the process will no doubt be expensive for any company.
Like other industries, in the pharmaceutical sector, as well, cost effective procurement is critical, which entices many pharmaceutical players, especially, in the generic industry not to go for such expensive process just to maintain the SCS.
A serious SCS related tragedy:
I would like to reinforce my argument on the importance of SCS with the following example of the ‘Heparin tragedy’ where the supply chain integrity was seriously violated with ‘ingeneuity’.
In the beginning of 2008, there were media reports on serious adverse drug events, some even fatal, with Heparin, a highly sulfated glycosaminoglycan of Baxter International. Heparin is widely used as an injectable anticoagulant. Baxter voluntarily recalled almost all their Heparin products in the U.S. Around 80 people died from contaminated Heparin products in the U.S. The US FDA reported that such contaminated Heparin was detected from at least 12 other countries.
A joint investigation conducted by Baxter and the US FDA ascertained that the Heparin used in batches associated with the serious adverse drug events was contaminated with Over Sulfated Chondroitin Sulfate (OSCS). It was reported that Heparin Scientific Protein Laboratories, Changzhou, China supplied Heparin to Baxter.
The cost of OSCS is just a fraction of the ingredient used in Heparin. Being driven by the criminal profiteering motive the manufacturers in Changzhou, China had reportedly used OSCS for highly sulfated glycosaminoglycan, as the former could not be detected by the pharmacopeia test in use, until 2008. This is because OSCS mimics Heparin in the pharmacopeia test. Post this criminal event, at present, all over the world more specific pharmacopeia test methods have been adopted for Heparin.
Stakeholders need to be extremely vigilant:
Considering all these, pharmaceutical players and the drug regulators from across the world should put proper ‘fool proof’ systems in place to eliminate the growing menace of criminal adulteration of APIs, drug intermediates, excipients entering in the supply chain together with preventing any breach in their logistics support systems.
Apprehension against generic drugs as a class:
Taking advantage of the situation, one can possibly say, as some vested interests have already started propagating that generic equivalents of the branded drugs are really not quite the same in quality.
However, the point that cannot be ignored is the comment of a senior USFDA, who was quoted in the same article saying, “I have heard it enough times from enough people to believe that there are a few products that aren’t meeting quality standards.“
Generic drug manufacturers should make serious note of such comments and act accordingly to allay prevailing lurking fear on the use of generic medicines, in general, though small in number.
Conclusion:
Following the recent series of incidents including that of Ranbaxy, the image of India as a low cost generic drugs manufacturer of high quality could get adversely impacted. Although there are enough instances that such things happen in the developed world, as well, including the United States.
Moreover, in the backdrop of high decibel quality concerns raised by USFDA, the level of apprehension regarding effectiveness of generic drugs made in India may increase significantly, unless some tangible, well thought out and highly publicized remedial measures are taken forthwith.
The decision of Jaslok Hospital, Mumbai advising their doctors for not using Ranbaxy products to patients on the same ground, will further strengthen the public apprehension.
Whatever may be the reason, as long as any company is in the business of manufacturing medicines, there should be demonstrable zero tolerance on any compromise, fraud or negligence in the drug quality standards. Any fraud and negligence in drug quality, I reckon, is virtually a fraud against humanity.
That said, changing mindset towards a strong corporate governance by walking the talk, all pharmaceutical companies must guarantee safe and high quality medicines to the society, come what may.
This, I believe, could be achieved by putting in place a robust SCS system and ensuring that this is not compromised in any way… anywhere…ever… for patients’ sake…both globally and locally.
By: Tapan J. Ray
Disclaimer: The views/opinions expressed in this article are entirely my own, written in my individual and personal capacity. I do not represent any other person or organization for this opinion.